OxyFile #612

Treatment of severe Raynaud's syndrome by injection of autologous 
blood pretreated by heating, ozonation and exposure to ultraviolet 
light (H-O-U) therapy.

Cooke ED; Pockley AG; Tucker AT; Kirby JD; Bolton AE 

Clinical Microvascular Unit, St. Bartholomew's Hospital, 
London, UK.

Int Angiol, 1997 Dec, 16:4, 250-4 


OBJECTIVE: To determine the effect of re-injection of small 
samples of autologous blood, pretreated with heat, ozone and 
ultraviolet light (H-O-U therapy) in patients with severe 
Raynaud's syndrome.

EXPERIMENTAL DESIGN: Open trial in 4 patients. 

SETTING: Temperature/humidity controlled vascular laboratory. 

PATIENTS: Severe Raynaud's syndrome of more than 5 years duration 
and defined as more than 5 attacks daily or 10 attacks in one 
week, at least half of which were painful and lasting for more 
than 30 minutes. Three patients were refractory to infusions of 

INTERVENTIONS: Patients were treated daily or on alternate days 
for a two to three weeks period by re-injection of citrated 
autologous blood pre-treated with heat, ozone and ultraviolet 
light (H-O-U therapy). MEASURES: Clinical observations; mean 
equilibrated hand temperature (infrared thermography); 
distributive and microcirculatory blood-flow (venous occlusion 
strain-gauge plethysmography, infrared photoplethysmography, laser 
Doppler flowmetry) iontophoresis of acetylcholine and sodium 
nitroprusside; estimations: serum levels of 6-keto-PGF1alpha and 
serum levels of anti-hsp65 antibody. 

RESULTS: Reduction or abolition of Raynaud's attacks for at least 
three months after treatment. Mean equilibrated hand temperature 
increased but did not normalise. Blood flow parameters improved 
but did not reach statistical significance. Iontophoresis of 
acetylcholine showed an increase in laser Doppler flowmetry which 
was statistically significant. Serum levels of 6-keto-PGF1alpha, 
fell significantly in three patients. Serum levels of anti-hsp65 
antibody fell in the one patient which was followed sequentially. 
CONCLUSIONS: H-O-U therapy may prove useful in patients with 
severe Raynaud's syndrome.